Field report describes nirsevimab rollout for RSV prevention in New York City infants

This field report describes the public health rollout of nirsevimab for Respiratory Syncytial Virus (RSV) prevention. The population of interest was infants born during the recommended nirsevimab administration period in New York City. The report focuses on the percentage of infants who received the monoclonal antibody, but no specific numerical results, effect sizes, or absolute numbers are provided in the abstract.

No comparator group is reported, and the study design is observational and descriptive in nature. The abstract does not report any safety or tolerability data, including adverse events, serious adverse events, or discontinuations. Follow-up duration and the final sample size are also not reported.

Key limitations stem from the nature of the report as a field description rather than a formal study. The absence of specific results, comparative data, and safety information prevents any assessment of the rollout's effectiveness or safety profile. The practice relevance is not reported, and the funding sources or potential conflicts of interest are not disclosed. This report serves as a descriptive account of an implementation process without providing evaluative outcomes.